The Latin America, Middle East and Africa Osteoporosis Drugs Market is expected to witness market growth of 5.3% CAGR during the forecast period (2020-2026).
Vitamin D deficiency is prevalent in the Middle East and Africa regions, despite the abundance of sunshine during the day. The rate of death after osteoporotic fracture in the area is 2-3 times that of Western societies. The main reason for this is a lack of utilities, with less than one DXA scan for 1 million people in Morocco. Among postmenopausal women, 53.9 percent had osteopenia and 28.4 had osteoporosis. Hip fractures have risen from 1008 a year in 2008 to four times the initial level in 2050.
The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration
By Drug Class
By Country
Companies Profiled
Unique Offerings from the Publisher
Vitamin D deficiency is prevalent in the Middle East and Africa regions, despite the abundance of sunshine during the day. The rate of death after osteoporotic fracture in the area is 2-3 times that of Western societies. The main reason for this is a lack of utilities, with less than one DXA scan for 1 million people in Morocco. Among postmenopausal women, 53.9 percent had osteopenia and 28.4 had osteoporosis. Hip fractures have risen from 1008 a year in 2008 to four times the initial level in 2050.
The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration
- Oral
- Injectable and
- Other Route of Administration
By Drug Class
- Bisphosphonates
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM) and
- Other Drug Classes
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Osteoporosis Drugs Market by Route of Administration
Chapter 4. LAMEA Osteoporosis Drugs Market by Drug Class
Chapter 5. LAMEA Osteoporosis Drugs Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
Methodology
LOADING...
